<DOC>
	<DOCNO>NCT03090893</DOCNO>
	<brief_summary>The objective study prospectively evaluate response continuous infusion recombinant human antithrombin concentrate ( rhAT ) ( ATRYN® ) achieve maintain AT activity within specify range adult patient require extracorporeal membrane oxygenation ( ECMO ) follow cardiopulmonary bypass ( CPB ) cardiac surgery .</brief_summary>
	<brief_title>Response Continuous Recombinant Antithrombin Infusion Postcardiotomy ECMO Patients</brief_title>
	<detailed_description />
	<mesh_term>Antithrombin III Deficiency</mesh_term>
	<mesh_term>Thrombophilia</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>Completed cardiac surgery Cardiopulmonary Bypass subsequently place venoarterial ( VA ) Extracorporeal Membrane Oxygenation ( ECMO ) support point ongoing hospitalization Serum Antithrombin &lt; 60 % . Heart transplantation ongoing hospitalization Excessive bleeding ( 300 ml/hr chest tube drainage 2 consecutive hour ) Weight &lt; 40 kg Allergy goat product Anticoagulation direct thrombin inhibitor Religious exception blood product Hypothermia ( &lt; 34°C )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>